Idiotype Vaccines in the Treatment of B-Cell Non-Hodgkin's Lymphoma

References

• SEER Cancer Statistics Review, 1973–1999. National Cancer Institute, Bethesda, MD 2002, http://seer.cancer.gov/csr/1973_1999/
   Google Scholar
• Horning S. J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin. Oncol. 1993; 20(5 Suppl 5)75–88, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Grillo-Lopez A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabinanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J. Clin. Oncol. 1998; 16(8)2825–2833, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Davis T. A., Grillo-Lopez A. J., White C. A., McLaughlin P., Czuczman M. S., Link B. K., Maloney D. G., Weaver R. L., Rosenberg J., Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma; safety and efficacy of re-treatment. J. Clin. Oncol. 2000; 18(17)3135–3143, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Davis T. A., Czerwinski D. K., Levy R. Therapy of b-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 expression. Clin. Cancer Res. 1999; 5: 611–615, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stevenson G. T., Stevenson F. K. Antibody to molecularly-defined antigen confined to a tumour cell surface. Nature 1975; 254(5502)714–716, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Campbell M. J., Carroll W., Kon S., Thielemans K., Rothbard J. B., Levy S., Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 1987; 139(8)2825–2833, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• George A. J., Tutt A. L., Stevenson F. K. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J. Immunol. 1987; 138(2)628–634, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Miller R. A., Hart S., Samoszuk M., Coulter C., Brown S., Czerwinski D., Kelkenberg J., Rowyston I., Levy R. Shared idiotypes expressed by human B-cell lymphomas. N. Engl. J. Med. 1989; 321(13)851–857, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Campbell M. J., Esserman L., Byars N. E., Allison A. C., Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 1990; 145(3)1029–1036, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lauritzen G. F., Weiss S., Dembic Z., Bogen B. Native idiotype specific CD4 + T cells and immunosurveillance of B-cell tumors. Proc. Natl. Acad. Sci. U. S. A. 1994; 91(12)5700–5704, [CSA]
   PubMed Web of Science ®Google Scholar
• Cao W., Myers-Powell B. A., Braciale T. J. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J. Exp. Med. 1994; 179(1)195–202, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chakrabarti D., Ghosh S. K. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. II: Characterization of anti-idiotypic CTL lines and clones. Cell. Immunol. 1992; 144(2)443–454, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Miller R. A., Maloney D. G., Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 1982; 306(9)517–522, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Meeker T. C., Lowder J., Maloney D. G., Miller R. A., Thielemans K., Warnke R., Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65(6)1349–1363, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Meeker T., Lowder J., Cleary M. L., Stewart S., Warnke R., Sklar J., Levy R. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 1985; 312(26)1658–1665, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lynch R. G., Graff R. J., Sirisinha S., Simms E. S., Eisen H. N. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. U S A 1972; 69(6)1540–1544, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Stevenson F. K., Gordon J. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J. Immunol. 1983; 130(2)970–973, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Campbell M. J., Carroll W., Kon S., Thielemans K., Rothbard J. B., Levy S., Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 1987; 139(8)2825–2833, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kaminski M. S., Kitamura K., Maloney D. G. Idiotype vaccination against murine B cell lymphoma; Inhibition of tumor immunity by free idiotype protein. J. Immunol. 1987; 138(4)1289–1296, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Caspar C. B., Levy S., Levy R. Idiotype vaccines for non-Hodgkin's Lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 1997; 90(9)3699–3706, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Campbell M. J., Esserman L., Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J. Immunol. 1988; 141(9)3227–3233, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Campbell M. J., Esserman L., Byars N. E., Allsion A. C., Levy R. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. Int. Rev. Immunol. 1989; 4(4)251–270, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Kwak L. W., Campbell M. J., Czerwinski D. K., Hart S., Miller R. A., Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 1992; 327(17)1209–1215, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Carroll W. L., Thielemans K., Dilley J., Levy R. Mouse χ human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 1986; 89(1)61–72, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hsu F. J., Caspar C. B., Czerwinski D., Kwak L. W., Liles T. M., Syrengelas A., Taidi-Laskowski B., Levy R. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long term results of a clinical trial. Blood 1997; 89(9)3129–3135, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Greenberg P. D. Adoptive T-cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 1991; 49: 281–355, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Shu S., Chou T., Rosenberg S. A. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J. Immunol. 1987; 139(1)295–304, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kwak L. W., Young H. A., Pennington R. W., Weeks S. D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte-macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. U. S. A. 1996; 93(20)10972–10977, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pardoll D. M. Cancer vaccines. Nat. Med. 1998; 4(suppl)525–531, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• de Gruil T. D., Curiel D. T. Cancer vaccine strategies get bigger and better. Nat. Med. 1999; 10(5)1124–1125, [CROSSREF]
   Google Scholar
• Bendandi M., Gocke C. D., Kobrin C. B., Benko F. A., Sternas L. A., Pennington R., Watson T. M., Reynolds C. W., Gause B. L., Duffey P. L., Jaffe E. S., Creekmore S. P., Longo D. L., Kwak L. W. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 1999; 5(10)1171–1177, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lee M. S., Chang K. S., Cabanillas F., Freireich E. J., Trujillo J. M., Stass S. Detection of minimal residual disease carrying the t(14:18) by DNA sequence amplification. Science 1987; 237(4811)175–178, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freedman A., Woo S. D., Blake D., Shu R. S., Freeman G., Gongtine J. A., Pinkus G. S., Nadler L. M. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78(12)3275–3280, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y. J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000; 18: 767–811, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Timmerman J. M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 1999; 50: 507–529, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Flamand V., Somasse T., Thielemans K., Demanet C., Bakkus M., Bazin H., Tielemans F., Leo O., Urbain J., Moser M. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 1994; 24(3)605–610, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hsu F. J., Benike C., Fagnoni F., Liles T. M., Czerwinski D., Taidi B., Engleman E. G., Levy R. Vaccination of patients with B-cell lymphoma using antigen-pulsed dendritic cells. Nat. Med. 1996; 2(1)52–58, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Timmerman J. M., Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J. Immunol. 2000; 164(9)4797–4803, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Timmerman J. M., Czerwinski D. K., Davis T. A., Hsu F. J., Benike C., Hao X. M., Taidi B., Rajapaksa R., Caspar C. B., Okada C. Y., van Beckhoven A., Liles T. M., Engleman E. G., Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99(5)1517–1526, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kunkel L. A., Denney D. W., Mason K., King S., Ingolia D. Custom-made idiotype immunotherapies produced by High Throughput Gene Expression Technology (Hi-GET™) for follicular non-Hodgkin's lymphoma patients. J. Clin. Oncol. 2002; 21: 77a
   Google Scholar
• Timmerman J., Czerwinski D., van Beckhoven A., Vose J., Ingolia D., Kunkel L., Denney D., Levy R. A phase I/II trial to evaluate the immunogenicity of recombinant idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma. Blood 2000; 96(11)2481
   Google Scholar
• Timmerman J., Vose J., Kunkel L., Bierman P., Czerwinski D., Hohenstein M., Ingolia D., Denney D., Levy R. A phase 2 study demonstrating recombinant idiotype vaccine elicits specific anti-idiotype immune responses in aggressive non-Hodgkin's lymphoma. Blood 2001; 98(11)1440, [CSA]
   PubMedGoogle Scholar
• Timmerman J., Levy R., Czerwinski D., Ingolia D., Denney D., Kunkel L. A phase 2 trial to evaluate the efficacy of recombinant idiotype vaccines in untreated follicular non-Hodgkin's lymphoma in the “watch and wait” period. J. Clin. Oncol. 2002; 21: 13
   Google Scholar
• McCormick A. A., Kumagal M. H., Hanley K., Turpen T. H., Hakim I., Grill L. K., Tuse D., Levy S., Levy R. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl. Acad. Sci. U. S. A. 1999; 96(2)703–708, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Reddy S. A., Czerwinski D., Rajapaksa R., Reinl S., Garger S. J., Cameron T., Barrett J., Novak J., Holtz R. B., Levy R. Plant derived single-chain Fv idiotype vaccines are safe and immunogenic in patients with follicular lymphoma: results of a phase I study. Blood 2002; 100(11)609
   Google Scholar
• Hawkins R. E., Winter G., Hamblin T. J., Stevenson F. K., Russell S. J. A genetic approach to idiotypic vaccination. J. Immunol. 1993; 14(4)273–278
   Google Scholar
• Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. 1999; 73: 329–368, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Krieg A. M., Yi A., Schorr J., Davis H. L. The role of CpG dinucleotides in DNA vaccines. Trends Micorobiol. 1998; 6(1)23–37, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stevenson F. K., Zhu D., King C. A., Ashworth L. J., Kumar S., Hawkins R. E. Idiotypic DNA vaccines against B-cell lymphoma. Immunol. Rev. 1995; 145: 211–228, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Spellerberg M. F., Zhu D., Thompsett A., King C. A., Hamblin T. J., Stevenson F. K. DNA vaccines against lymphoma. Promotion of anti-idiotypic responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J. Immunol. 1997; 159(4)1885–1892, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Valmori D., Pessi A., Bianchi E., Corradin G. Use of human universally antigenic tetanus toxoid T cell epitopes as carriers for human vaccination. J. Immunol. 1992; 149(2)717–721, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• King C. A., Spellerberg M. B., Zhu D., Rice J., Sahota S. S., Thompsett A. R., Hamblin T. J., Radl J., Stevenson F. K. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 1998; 4(11)1281–1286, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Syrengelas A. D., Chen T. T., Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 1996; 2(9)1038–1041, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Timmerman J. M., Singh G., Hermanson G., Hobart P., Czerwinski D. K., Taidi B., Rajapaksa R., Caspar C. B., van Beckhoven A., Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002; 62(20)5845–5852, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar